Uploaded December 2012 | Updated November 2026, 2 hours ago
Infinity Pharmaceuticals (NASDAQ:INFI) popular in today's session after shares of the company surged to their highest level in a decade yesterday. The company announced positive results from its clinical trial of its drug IPI-145, a treatment for blood cancers. This caused it's stock to increase 21.4 percent to $27.35, close to the day's peak of $27.60.
The study on this new drug is not over and is still not approved for sale yet. But, Infinity says it was active against advanced blood cancers like chronic lymphocytic leukemia and Hodgkin's lymphoma, making it a very desirable drug.
Infinity Pharmaceuticals could continue to rise in today's session. Premarket, its stock was up just a half a percent.
Infinity Pharmaceuticals (NASDAQ:INFI) popular in today's session after shares of the company surged to their highest level in a decade yesterday. The company announced positive results from its clinical trial of its drug IPI-145, a treatment for blood cancers. This caused it's stock to increase 21.4 percent to $27.35, close to the day's peak of $27.60.
The study on this new drug is not over and is still not approved for sale yet. But, Infinity says it was active against advanced blood cancers like chronic lymphocytic leukemia and Hodgkin's lymphoma, making it a very desirable drug.
Infinity Pharmaceuticals could continue to rise in today's session. Premarket, its stock was up just a half a percent.










